



13th International Symposium
on Endovascular Therapeutics

EVAR USING THE ALTURA ENDOGRAFT SYSTEM WITH DOUBLE-D PROXIMAL STENT DESIGN, PRECISE RENAL ARTERY POSITIONING AND RETROGRADE DEPLOYMENT OF ILIAC STENT GRAFT: SINGLE CENTRE CLINICAL EXPERIENCE

Dainis Krievins

*Professor of Vascular Surgery
University of Latvia, Stradins University hospital*



PAULS STRADINS

CLINICAL UNIVERSITY HOSPITAL



Disclosure

Lombard Medical Ltd., Endologix Ltd.

X I have the following potential conflicts of interest to report:

X Receipt of grants/research support

Receipt of honoraria and travel support

Employment in industry

Shareholder in a healthcare company

Owner of a healthcare company

I do not have any potential conflict of interest

Limitations Of Current EVAR

- **Anatomical**
- **Procedural**
 - Unpredictable and time consuming
 - Gate cannulation, Snaring, Polymer
 - Complex procedures
- **Economical**
 - Throughput / efficiency
 - Device costs

Aortic

- Length/shape of neck
- Angulation
- Small distal segment

Iliac

- Tortuosity
- Small caliber access



Other


- Landing zone/fixation
- Thrombus/Calcification

***Design Goal: Address current EVAR limitations
with a simple, low profile system***

Parallel / “Kissing” endografts



NELLIX



ALTURA




ALTURA System Concept

- **Stent Graft**

- “D” endografts (aortic)
- Flexible Nitinol braid
- Ribbed woven polyester outside the stent
- Suprarenal anchors
- Telescoping iliac endografts

- **Delivery System**

- Low profile (14F) and flexible
- Controlled braid deployment
- No Gate Cannulation
- Contrast injection capability




Aortic Deployment

Introduce and align 'D' endografts




Aortic Deployment

Position endografts below both renals



Aortic Deployment


Release suprarenal stent and deploy




Iliac Deployment

Start at Iliac bifurcation

Reverse deployment
from distal to proximal graft




*Built-in contrast
injection capability to
identify internal iliac*



Nitinol Braided Stents

- Well known for ***extreme flexibility****
- Successful applications in other challenging vasculature
- Proven long term ***excellent durability*** and fatigue strength*
- Disadvantages
 - Length control
 - Hoop strength (addressed by newer stents)


Braided stent Vs. Laser Cut Nitinol**



Wouldn't a braided stent be great for EVAR ?

Bringing Braided Stent Flexibility to EVAR...

Top Down Aortic Deployment



- Offset deployment
- Repositionability

Bottom Up Iliac Deployment



- Retrograde deployment
- Preservation of hypogastrics

| Challenge | Solution |
|----------------|---|
| Length Control | Make length variations irrelevant by starting deployment at branch vessels (renals and hypogastric) |

Larger overlap zone:

- Absorbs length variability
- Simplifies iliac length selection



Latvia Experience with *ALTURA*

- 1st Case Performed: Jan 2014



Clinical Trial Experience and Evolution

FIH / Feasibility

Standard

- n = 47 enrolled
- Standard anatomy
- Chile & Latvia

⊙ > 4.5cm
Neck ≥ 15mm
Neck ≤ 60°

Complex

- n = 10
- Complex anatomy
- Chile & Latvia

Proof of
Concept
&
Safety
Evaluation

ELEVATE registry

Standard & Complex

- n = 46
- Standard anatomy
- OUS sites (8 sites Europe & Chile)

CE mark granted July 2015

Further development

Altitude Registry

Standard

- Enrollment 2017
- International prospective registry
- N= up to 1000
- Capture real world use of Altura Endograft system and its impact on:
 - Safety and efficacy
 - Unique features of the design
 - Impact on procedure
 - Impact on patient care

Latvia Experience with *ALTURA*

- Total 104 cases to date



FIM
(Standard/Extreme)

- n = 12
- Standard/Complex anatomy





ELEVATE
International
(Standard)

- n = 16
- Standard anatomy



ALTITUDE
(Standard)

- n = 35
- Standard anatomy



ALTURA Clinical Trial Experience Latvia RESULTS

| Demographics & Baseline Characteristics | 104 Patients |
|---|--------------|
| Male Gender (%) | 87.8 |
| Age, Years, Mean, Range | 72.8 ± 8.3 |
| History of Coronary artery disease (%) | 66.3 |
| Hypertension (%) | 62.5 |
| Family history of AAA (%) | 5.7 |
| | |
| Mean AAA Sac Diameter, cm | 5.7 ± 0.6 |
| Mean Neck Vessel Diameter, mm | 22.0 ± 8.5 |
| Mean Neck Length, mm | 22.3 ± 7.7 |

ALTURA Clinical Trial Experience Latvia RESULTS

| Procedural / In-Hospital Outcomes | | 104 Patients |
|-------------------------------------|-----------------|----------------|
| Procedural Technical Success, N | | 104/104 (100%) |
| Mean Fluoroscopy Time, min | | 24 ± 11 |
| Mean Total Procedure Time, min | | 52 ± 36 |
| Vessel Access Type percutaneous (%) | | 98.8 |
| Anesthesia Type (%) | | |
| | Local | 4.8 |
| | Regional/Spinal | 85.6 |
| | General | 9.6 |
| Post-procedure ICU, N | | 8/104 |
| Time to Hospital Discharge, days | | 2.8 ± 1.4 |

ALTURA Clinical Trial Experience Latvia RESULTS

| Evaluation (mean 31.5 months) | 30 Days (N = 104) | 1 YR (N= 64) | 2 YRS (N = 33) | 3 YRS (N = 20) | 4 YRS (N = 14) |
|-------------------------------------|-----------------------|-----------------------|------------------------|-----------------------|-------------------|
| Aneurysm Rupture | 0 | 0 | 0 | 0 | 0 |
| No AAA related M | 0 | 4 | 0 | 2 | 1 |
| Device Migration (≥10mm) | 0 | 0 | 0 | 0 | 0 |
| Endoleak – Type Ia | 1 ¹ (1.0%) | 1 ² (1.5%) | 1 ³ (3.0%) | 0 | 0 |
| Endoleak – Type Ib | 0 | 0 | 1 ⁴ (3.0%) | 0 | 0 |
| Endoleak – Type III | 0 | 0 | 0 | 0 | 0 |
| Endoleak – Type II | 11 (11%) | 6 (9.3%) | 4 (12%) | 2 (10%) | 0 |
| Stent Occlusion | 0 | 1 ⁵ (1.6%) | 0 | 0 | 0 |
| Stent stenosis | 2(1.9%) | 0 | 0 | 0 | 0 |
| Fracture or Fatigue | 0 | 0 | 0 | 0 | 0 |
| Rate of Secondary Procedures | 1 (1.2%) | 2 (3.4%) | 4 ⁶ (12.1%) | 1 ⁶ (5.0%) | 0 |

¹ Intra-operative misplacement; Treated additional prox D-shapes

² Prox angle 90°; Treated coils + glue at 1 year

³ Prox neck degeneration; Treated coils + glue at 2 years

⁴ Large left iliac with thrombus and connection to lumbar, Treated: left iliac Coils+glue

⁵ Intra-operative stent damage with stenosis; stent thrombosed; explant with Ao-Biiliac graft

ALTURA Clinical Trial Experience

Iliac segment stenosis (*PTA*)



30 days



2 years



ALTURA Clinical Trial Experience

IB endoleak (*Out of IFU CIA*)




ALTURA Clinical Trial Experience


IB endoleak (*Treated with coils+glue*)




82 year old patient
































Pre treatment




1st month FU




Pre-op

4 Year follow-up

Surveillance Appearances




- Majority of patients had sac shrinkage



“D” Endograft Stability

No septal endoleaks




1 month

6 months

12 months

48 months



Summary

- The initial safety and effectiveness of the ALTURA device is very encouraging
 - Absence of rupture
 - Pleasing Endoleak and Occlusion performance, attributable to device/patient selection
 - Low rate of device-related secondary procedures



Conclusions

- Predictable, precise and easy to use
- Potential benefits include:
 - Tortuous, short iliacs
 - Narrow bifurcations
 - Offset renals
- Accurate placement due to repositionability
- No cannulation
- Quicker procedures
- Potential option for rAAA
- Potential option for EVAR day surgery patients

There is need for KISSING endografts





Thank You

